Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
CAMBRIDGE, Mass., May 10, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
Bank of America Merrill Lynch 2017 Health Care Conference
Wednesday, May 17, 2017 at 12:20 p.m. ET in Las Vegas, NV
UBS Global Healthcare Conference
Tuesday, May 23, 2017 at 9:00 a.m. ET in New York, NY
A webcast of each presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of each presentation will be posted on the Momenta website approximately one hour after each event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
